JP2011520959A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520959A5
JP2011520959A5 JP2011510515A JP2011510515A JP2011520959A5 JP 2011520959 A5 JP2011520959 A5 JP 2011520959A5 JP 2011510515 A JP2011510515 A JP 2011510515A JP 2011510515 A JP2011510515 A JP 2011510515A JP 2011520959 A5 JP2011520959 A5 JP 2011520959A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
pharmaceutical composition
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003174 external-priority patent/WO2009142759A1/en
Publication of JP2011520959A publication Critical patent/JP2011520959A/ja
Publication of JP2011520959A5 publication Critical patent/JP2011520959A5/ja
Pending legal-status Critical Current

Links

JP2011510515A 2008-05-23 2009-05-22 新規可溶性cd83ポリペプチド、配合物および使用法 Pending JP2011520959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12870908P 2008-05-23 2008-05-23
US61/128,709 2008-05-23
PCT/US2009/003174 WO2009142759A1 (en) 2008-05-23 2009-05-22 Novel soluble cd83 polypeptides, formulations and methods of use

Publications (2)

Publication Number Publication Date
JP2011520959A JP2011520959A (ja) 2011-07-21
JP2011520959A5 true JP2011520959A5 (enExample) 2012-07-05

Family

ID=41340432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510515A Pending JP2011520959A (ja) 2008-05-23 2009-05-22 新規可溶性cd83ポリペプチド、配合物および使用法

Country Status (12)

Country Link
US (1) US20110182903A1 (enExample)
EP (1) EP2288387B1 (enExample)
JP (1) JP2011520959A (enExample)
KR (2) KR101679084B1 (enExample)
CN (1) CN102036690B (enExample)
AU (1) AU2009249540B9 (enExample)
BR (1) BRPI0913577B1 (enExample)
CA (1) CA2725198A1 (enExample)
IL (1) IL209207A (enExample)
MX (1) MX2010012576A (enExample)
RU (1) RU2535340C2 (enExample)
WO (1) WO2009142759A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
CN103243119B (zh) * 2013-05-20 2016-03-30 中国科学技术大学 可溶性cd83的表达和制备方法
US20190315878A1 (en) 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
ES2954311T3 (es) 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
KR102282341B1 (ko) 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
EP3895723A1 (en) * 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
KR20010023325A (ko) * 1997-08-26 2001-03-26 리스 데브라 케이. 함지방세포-특이적 단백질 상동체
PT1223971E (pt) 1999-10-27 2005-10-31 Alexandra Lucas Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
EP1578366A4 (en) * 2002-10-09 2007-12-19 Tolerrx Inc MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF
EP1422241A1 (en) * 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
EP2789625B1 (en) * 2006-08-18 2018-06-06 Argos Therapeutics, Inc. Use of soluble CD83 for perfusing a tissue for transplantation

Similar Documents

Publication Publication Date Title
JP2011520959A5 (enExample)
RU2010152553A (ru) Новые растворимые полипептиды cd83, композиции и способы их применения
JP2017099391A5 (enExample)
JP2014530611A5 (enExample)
JP2014513953A5 (enExample)
JP2010511056A5 (enExample)
JP2010537638A5 (enExample)
JP2010162017A5 (enExample)
HRP20200230T1 (hr) Polipeptidi antitijela koji antagoniziraju cd40l
JP2014516945A5 (enExample)
EA035973B9 (en) Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same
JP2019504822A5 (enExample)
JP2019503167A5 (enExample)
FI3592384T3 (fi) Vasta-aineita, jotka spesifisesti sitoutuvat ihmisen IL-1R7:ään
JP2020521458A5 (enExample)
JP2010500005A5 (enExample)
Rai Peptide and protein mimetics by retro and retroinverso analogs
JP2012501669A5 (enExample)
JP2011144177A5 (enExample)
JP2007514419A5 (enExample)
JP2012500020A5 (enExample)
JP2014501510A5 (enExample)
JP2011518857A5 (enExample)
KR20220066035A (ko) 폴리펩타이드
RU2017134274A (ru) Связывающие tslp белки